Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

BACKGROUND: Determining the relative cost-effectiveness between advanced therapeutic options for ulcerative colitis (UC) may optimize resource utilization. We evaluated total cost per response, cost per remission, and cost of safety events for patients with moderately-to-severely active UC after 52 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Jairath, Vipul, Cohen, Russell D., Loftus, Edward V., Candela, Ninfa, Lasch, Karen, Schultz, Bob G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724317/
https://www.ncbi.nlm.nih.gov/pubmed/36474165
http://dx.doi.org/10.1186/s12876-022-02590-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724317/
https://www.ncbi.nlm.nih.gov/pubmed/36474165
http://dx.doi.org/10.1186/s12876-022-02590-6

Ejemplares similares